Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1830 in generalized myasthenia gravis
NCT04982289Phase 2Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of orilanolimab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Planned start Jan 2022; status: withdrawn.
02
Drugs
orilanolimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04982289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982289.